BACKGROUND/AIM: Patients with unresectable liver colorectal cancer metastases are treated with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing the mass of metastases and thus increasing the chances of resectability. Bevacizumab comprises an anti-VEGF (vascular endothelial growth factor) humanized IgG monoclonal antibody that is used for biological therapy purposes. It acts to inhibit angiogenesis, thereby slowing down the growth of metastases. Due to its being administered systematically, bevacizumab also exerts an effect on the surrounding healthy liver parenchyma and potentially limits the process of neovascularization and thus regeneration of the liver. Since the remnant liver volume forms an important factor in postoperative morbidity and mortality following a major hepatectomy, we decided to study the effect of bevacizumab on vascular and biliary microarchitecture in healthy liver parenchyma and its ability to regenerate following major hepatectomy. MATERIALS AND METHODS: We performed an experiment employing a large animal model where a total of 16 piglets were divided into two groups (8 piglets in the control group and 8 piglets in the experimental group with bevacizumab). All the animals were subjected to major hepatectomy and the experimental group was given bevacizumab prior to hepatectomy. All the animals were sacrificed after 4 weeks. We performed biochemical analyses at regular time intervals during the follow-up period. Histological examination of the liver tissue was performed following sacrifice of the animals. RESULTS: No statistical difference was shown between groups in terms of the biochemical and immunohistochemical parameters. The histological examination of the regenerating liver tissue revealed the higher length density of sinusoids in the experimental group. CONCLUSION: Bevacizumab does not act to impair liver regeneration following hepatectomy.

1st Department of Internal Medicine Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Orthopedics and Traumatology Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Plastic Surgery Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Radiology Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Surgery Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Surgery Medical School and Teaching Hospital in Pilsen Charles University Pilsen Czech Republic;

European Centre of Excellence NTIS Faculty of Applied Sciences University of West Bohemia Pilsen Czech Republic

See more in PubMed

Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol. 2020;11(10):761–808. doi: 10.5306/wjco.v11.i10.761. PubMed DOI PMC

Chow FC, Chok KS. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019;11(2):150–172. doi: 10.4254/wjh.v11.i2.150. PubMed DOI PMC

García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol. 2015;10(4):453–465. doi: 10.1007/s11523-015-0362-0. PubMed DOI PMC

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. doi: 10.1038/nrd1381. PubMed DOI

Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005;23(22):4853–4855. doi: 10.1200/JCO.2005.23.754. PubMed DOI

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. doi: 10.1056/NEJMoa032691. PubMed DOI

Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection. Dig Surg. 2012;29(1):6–17. doi: 10.1159/000335713. PubMed DOI

Li DB, Ye F, Wu XR, Wu LP, Chen JX, Li B, Zhou YM. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol. 2013;19(5):761–768. doi: 10.3748/wjg.v19.i5.761. PubMed DOI PMC

Millet G, Truant S, Leteurtre E, Hebbar M, Zerbib P, Huet G, Boleslawski E, Pruvot FR. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg. 2012;256(5):755–61. doi: 10.1097/SLA.0b013e31827381ca. discussion 761-2. PubMed DOI

Margonis GA, Buettner S, Andreatos N, Sasaki K, Pour MZ, Deshwar A, Wang J, Ghasebeh MA, Damaskos C, Rezaee N, Pawlik TM, Wolfgang CL, Kamel IR, Weiss MJ. Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases. J Surg Oncol. 2017;116(8):1150–1158. doi: 10.1002/jso.24769. PubMed DOI

Dupre A, Paradisi A, Langonnet S, Gandini A, Mehlen P, Rivoire M. Bevacizumab impairs hepatocyte proliferation after partial hepatectomy in a rabbit model. Anticancer Res. 2012;32(12):5193–5200. PubMed

Mori H, Saito YU, Iwahashi S, Ikemoto T, Imura S, Morine Y, Shimada M. Impact of bevacizumab on liver damage after massive hepatectomy in rats. In Vivo. 2019;33(5):1469–1476. doi: 10.21873/invivo.11626. PubMed DOI PMC

Klein P, Nalos L, Dejmek J, Soukup M. The method of long-term catheterization of the vena jugularis in pigs. J Pharmacol Toxicol Methods. 2019;98:106584. doi: 10.1016/j.vascn.2019.106584. PubMed DOI

Mik P, Tonar Z, Malečková A, Eberlová L, Liška V, Pálek R, Rosendorf J, Jiřík M, Mírka H, Králíčková M, Witter K. Distribution of connective tissue in the male and female porcine liver: histological mapping and recommendations for sampling. J Comp Pathol. 2018;162:1–13. doi: 10.1016/j.jcpa.2018.05.004. PubMed DOI

Mattfeldt T, Mall G, Gharehbaghi H, Möller P. Estimation of surface area and length with the orientator. J Microsc. 1990;159(Pt 3):301–317. doi: 10.1111/j.1365-2818.1990.tb03036.x. PubMed DOI

Malečková A, Kochová P, Pálek R, Liška V, Mik P, Bońkowski T, Horák M, Tonar Z. Blunt injury of liver: mechanical response of porcine liver in experimental impact test. Physiol Meas. 2021;42(2):025008. doi: 10.1088/1361-6579/abdf3c. PubMed DOI

Eberlova L, Maleckova A, Mik P, Tonar Z, Jirik M, Mirka H, Palek R, Leupen S, Liska V. Porcine liver anatomy applied to biomedicine. J Surg Res. 2020;250:70–79. doi: 10.1016/j.jss.2019.12.038. PubMed DOI

Saxena R. Philadelphia, Elsevier/Saunders. 2011. Practical hepatic pathology: A diagnostic approach. DOI

Mouton PR. Johns Hopkins University Press. 2001. Principles and Practices of Unibiased Stereology: An introduction for bioscientists.

Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, Nakagawa K, Yoshidome H, Kataoka M, Nakajima N. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol. 2001;34(5):683–689. doi: 10.1016/s0168-8278(00)00055-6. PubMed DOI

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi: 10.1016/j.ctrv.2020.102017. PubMed DOI

Nykonenko A, Vávra P, Zonča P. Anatomic peculiarities of pig and human liver. Exp Clin Transplant. 2017;15(1):21–26. PubMed

Böhm F, Köhler UA, Speicher T, Werner S. Regulation of liver regeneration by growth factors and cytokines. EMBO Mol Med. 2010;2(8):294–305. doi: 10.1002/emmm.201000085. PubMed DOI PMC

Kaur S, Anita K. Angiogenesis in liver regeneration and fibrosis: “a double-edged sword”. Hepatol Int. 2013;7(4):959–968. doi: 10.1007/s12072-013-9483-7. PubMed DOI

De Assuncao TM, Jalan-Sakrikar N, Huebert RC. Regenerative medicine and the biliary tree. Semin Liver Dis. 2017;37(1):17–27. doi: 10.1055/s-0036-1597818. PubMed DOI PMC

Gill S, Liu DM, Green HM, Sharma RA. Beyond the knife: the evolving nonsurgical management of oligometastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2018;38:209–219. doi: 10.1200/EDBK_200941. PubMed DOI